MFICL Q1 2026 Earnings EPS Beat Supports Stable Performance Amid Steady Portfolio Armata Pharmaceuticals Q1 2026 Earnings Significant EPS Miss but Stock Rises on Pipeline Progress CAAP Q1 2026 Earnings EPS Misses Consensus by 75 as Operating Costs Weigh Milestone Pharmaceuticals Q1 2026 Earnings ClinicalStage Biotech Reports Wider Loss Than Expected SHEL Q1 2026 Earnings Strong EPS Beat Helped by Robust Operations Stock Edges Lower AIR Q1 2026 Earnings EPS Surpasses Estimates Amid Strong Demand in Aviation Services